Yasuto Takeuchi
Overview
Explore the profile of Yasuto Takeuchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
427
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shimose S, Saeki I, Ito T, Takeuchi Y, Tani J, Tomonari T, et al.
Hepatol Int
. 2025 Feb;
PMID: 40019708
Background: This study aimed to investigate the changes in oncological resection status in patients with unresectable hepatocellular carcinoma (u-HCC) receiving atezolizumab plus bevacizumab (Atez/Bev) and the impact of conversion therapy...
2.
Okubo S, Takaki A, Sato I, Adachi T, Takeuchi Y, Sue M, et al.
Intern Med
. 2025 Feb;
PMID: 39924239
Objective Identifying patients at high risk of steatotic liver disease (SLD) is crucial. The liver fibrosis stage is the most reliable marker of liver-related mortality. However, noninvasive risk stratification methods...
3.
Matsumoto K, Uchida D, Takeuchi Y, Kato H, Fujii Y, Harada K, et al.
DEN Open
. 2025 Jan;
5(1):e70073.
PMID: 39885893
Objectives: Endoscopic ultrasonography (EUS)-guided radiofrequency ablation has recently been introduced as one of the management strategies for small pancreatic neuroendocrine neoplasms (PNENs). However, prospective data on its safety and efficacy...
4.
Sasaki Y, Matsumoto K, Takaki A, Adachi T, Takahara M, Ozato K, et al.
Gastro Hep Adv
. 2024 Nov;
3(8):1138-1147.
PMID: 39559295
Background And Aims: Methods for predicting therapeutic response to immune checkpoint inhibitors in cancer therapy are in high demand. In patients with advanced hepatocellular carcinoma (HCC), atezolizumab (anti-programmed cell death-ligand...
5.
Uchida Y, Kurimoto R, Chiba T, Matsushima T, Oda G, Onishi I, et al.
EMBO Rep
. 2024 Oct;
25(12):5352-5382.
PMID: 39420119
Triple-negative breast cancer (TNBC) lacks the expression of hormone and HER2 receptors and is highly malignant with no effective therapeutic targets. In TNBC, the cancer stem-like cell (CSC) population is...
6.
Saeki I, Shimose S, Tomonari T, Ito T, Tani J, Takeuchi Y, et al.
PLoS One
. 2024 Sep;
19(9):e0311084.
PMID: 39321197
Durvalumab plus tremelimumab (Durva/Treme) combined immunotherapy is the first-line therapy recommended for unresectable hepatocellular carcinoma (HCC). Since sequential therapy is more effective in improving prognosis, tumor markers have been used...
7.
Shimose S, Saeki I, Tomonari T, Ito T, Tani J, Takeuchi Y, et al.
Oncol Lett
. 2024 Jul;
28(2):397.
PMID: 38979550
Although durvalumab plus tremelimumab (Dur/Tre) has been approved as first-line therapy for patients with unresectable hepatocellular carcinoma (u-HCC), its outcomes in real-world clinical practice are unclear. The present study aimed...
8.
Ito T, Takeuchi Y, Mizuno K, Imai M, Yoshimaru Y, Abe K, et al.
Hepatol Res
. 2024 Jun;
54(8):719-726.
PMID: 38884591
With the widespread use of immune checkpoint inhibitors (ICIs), liver injury (ICI-induced liver injury) as an immune-related adverse event has become a major concern in clinical practice. Because severe cases...
9.
Sue M, Takeuchi Y, Hirata S, Takaki A, Otsuka M
Cancers (Basel)
. 2024 May;
16(10).
PMID: 38791890
The neutrophil -to-lymphocyte ratio (NLR) is useful for predicting the effectiveness of treatment with immune checkpoint inhibitors (ICIs) and immune-related adverse events (irAEs). Because a growing body of evidence has...
10.
Kikuchi T, Takeuchi Y, Nouso K, Kariyama K, Kuwaki K, Toshimori J, et al.
Liver Int
. 2024 May;
44(7):1736-1737.
PMID: 38717049
No abstract available.